Posted: 27 November 2024
Optiscan has been featured in Stockhead and The Australian regarding its partnership with the University of Minnesota to advance cancer detection in pets. This collaboration focuses on utilizing Optiscan’s confocal endomicroscope imaging system to diagnose and treat cancer in companion animals, particularly cats and dogs.
The research agreement formalizes an earlier memorandum of understanding and aims to develop clinical data to support full FDA approval for veterinary use. Optiscan’s technology enables non-invasive, real-time imaging of cancerous cells, which can significantly improve diagnostic accuracy without the need for biopsies.
This partnership comes at a time when over 12 million pets in the U.S. are diagnosed with cancer annually, with breast and oral cancers being the most prevalent. Optiscan’s CEO, Dr. Camile Farah, highlighted the significance of this milestone, stating, “It marks another significant milestone in our efforts to demonstrate that the medical benefits derived from Optiscan’s technology platform extend beyond the treatment of humans.”
